Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRX518 + gemcitabine
- Development stage
- Unknown
- Lead developer
- Leap Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
TRX518 + gemcitabine is an investigational combination therapy for cancer. TRX518 is a humanized monoclonal antibody that targets the glucocorticoid-induced TNF receptor–related protein (GITR) on T cells. By agonizing GITR, TRX518 enhances immune responses against tumors by activating effector T cells and reducing immunosuppressive regulatory T cells within the tumor microenvironment[1][2][4][5]. Gemcitabine is a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis by incorporating into DNA during replication, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells[6][8]. The combination has been studied in early-phase clinical trials for advanced solid tumors to assess safety and preliminary efficacy[2].
- Other names
- anti-human GITR monoclonal antibody trx518anti-GITR monoclonal antibody2',2'-difluorodeoxycytidine
02
Targets
TNFRSF18 (GITR)RRM1POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on TRX518 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRX518 + gemcitabine.